<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00700778</url>
  </required_header>
  <id_info>
    <org_study_id>06827</org_study_id>
    <secondary_id>06827</secondary_id>
    <secondary_id>R21CA124522</secondary_id>
    <nct_id>NCT00700778</nct_id>
  </id_info>
  <brief_title>Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations</brief_title>
  <official_title>Genomic Markers of Breast Cancer Prevention Induced by HCG in Women at High Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use&#xD;
      of recombinant human chorionic gonadotropin may prevent breast cancer in premenopausal women&#xD;
      with BRCA1 mutations.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying recombinant human chorionic gonadotropin in&#xD;
      preventing breast cancer in premenopausal women with BRCA1 mutations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine whether the genomic profiles of breast epithelial cells of high-breast&#xD;
           cancer-risk women, as defined by their positive BRCA1 status and nulliparous condition,&#xD;
           express a signature indicative of high-risk.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine whether women identified to express a &quot;high-breast cancer-risk&quot; signature will&#xD;
           revert it to a &quot;low-risk&quot; signature after a 90-day treatment with r-hCG, which should&#xD;
           have induced breast differentiation and genomic changes that would serve as biomarkers&#xD;
           indicative of decreased breast cancer risk.&#xD;
&#xD;
      OUTLINE: Patients receive recombinant human chorionic gonadotropin subcutaneously three times&#xD;
      weekly. Treatment continues weekly for 90 days in the absence of unacceptable toxicity.&#xD;
&#xD;
      Benign breast tissue specimens are collected by core needle biopsy at baseline, day 90, and&#xD;
      day 270. Tissue samples are analyzed by cytopathology for epithelial normality, Ki67&#xD;
      immunohistochemical staining for cell proliferation, cDNA microarray for gene expression, and&#xD;
      serum studies for hormone levels and biomarker determinations.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 24 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to recruit volunteers&#xD;
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Gene Expression in Breast Epithelial Cells Obtained for Asymptomatic High Breast Cancer Risk Nulliparous Premenopausal Women at Baseline, After Treatment With r-hCG at 90 Days, and at 270 Days From Baseline</measure>
    <time_frame>90 days and 270 days from baseline</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>BRCA1 Mutation</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Recombinant human chorionic gonadotropin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive recombinant human chorionic gonadotropin subcutaneously three times weekly. Treatment continues weekly for 90 days in the absence of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant human chorionic gonadotropin</intervention_name>
    <arm_group_label>Recombinant human chorionic gonadotropin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
    <arm_group_label>Recombinant human chorionic gonadotropin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <arm_group_label>Recombinant human chorionic gonadotropin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Recombinant human chorionic gonadotropin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>needle biopsy</intervention_name>
    <arm_group_label>Recombinant human chorionic gonadotropin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Asymptomatic women who have a deleterious mutation on the BRCA1 gene&#xD;
&#xD;
          -  Normal, no complaints, no evidence of disease&#xD;
&#xD;
          -  Nulliparous, never pregnant (G0P0)&#xD;
&#xD;
          -  No previous diagnosis of breast or ovarian cancer&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status (PS) 0-1 OR Karnofsky PS 90-100%&#xD;
&#xD;
          -  Premenopausal with normal menstrual cycles and intact ovaries&#xD;
&#xD;
          -  Normal ovarian size report from pelvic ultrasound&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to human chorionic gonadotropin preparations or one of its&#xD;
             excipients&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including any of the following:&#xD;
&#xD;
               -  Ovarian enlargement of undetermined origin&#xD;
&#xD;
               -  Ovarian cysts &gt; 2 cm&#xD;
&#xD;
               -  Microcystic ovaries, which might predispose to the development of ovarian&#xD;
                  hyperstimulation syndrome&#xD;
&#xD;
               -  History of prior cancer other than non-melanoma skin cancer&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Severe cognitive deficit or psychiatric illness/social situations that would make&#xD;
                  her unable to give informed consent or would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 6 weeks since prior and no concurrent oral contraceptives or&#xD;
             hormone-replacement therapy&#xD;
&#xD;
          -  No concurrent tamoxifen for chemoprevention&#xD;
&#xD;
          -  No concurrent participation in another chemopreventive trial for breast cancer&#xD;
&#xD;
          -  No concurrent medication that could interfere with this study including any of the&#xD;
             following:&#xD;
&#xD;
               -  Hormonal contraceptives&#xD;
&#xD;
               -  Androgens&#xD;
&#xD;
               -  Prednisone&#xD;
&#xD;
               -  Thyroid hormones&#xD;
&#xD;
               -  Insulin&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No recent treatment with follicle-stimulating hormone for assisted reproduction&#xD;
&#xD;
          -  No HIV-positive patients on concurrent combination antiretroviral therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Russo, MD, FCAP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik fuer Frauenheilkunde</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 18, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <results_first_submitted>January 4, 2021</results_first_submitted>
  <results_first_submitted_qc>January 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2021</results_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>BRCA1 mutation carrier</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Recombinant Human Chorionic Gonadotropin</title>
          <description>Patients receive recombinant human chorionic gonadotropin subcutaneously three times weekly. Treatment continues weekly for 90 days in the absence of unacceptable toxicity.&#xD;
recombinant human chorionic gonadotropin&#xD;
microarray analysis&#xD;
immunohistochemistry staining method&#xD;
laboratory biomarker analysis&#xD;
needle biopsy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inconclusive data due to inadequate sample collection</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No results were obtained</population>
      <group_list>
        <group group_id="B1">
          <title>Recombinant Human Chorionic Gonadotropin</title>
          <description>Patients receive recombinant human chorionic gonadotropin subcutaneously three times weekly. Treatment continues weekly for 90 days in the absence of unacceptable toxicity.&#xD;
recombinant human chorionic gonadotropin&#xD;
microarray analysis&#xD;
immunohistochemistry staining method&#xD;
laboratory biomarker analysis&#xD;
needle biopsy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>No results were obtained</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Gene Expression in Breast Epithelial Cells Obtained for Asymptomatic High Breast Cancer Risk Nulliparous Premenopausal Women at Baseline, After Treatment With r-hCG at 90 Days, and at 270 Days From Baseline</title>
        <time_frame>90 days and 270 days from baseline</time_frame>
        <population>No results were obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Chorionic Gonadotropin</title>
            <description>Patients receive recombinant human chorionic gonadotropin subcutaneously three times weekly. Treatment continues weekly for 90 days in the absence of unacceptable toxicity.&#xD;
recombinant human chorionic gonadotropin&#xD;
microarray analysis&#xD;
immunohistochemistry staining method&#xD;
laboratory biomarker analysis&#xD;
needle biopsy</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Gene Expression in Breast Epithelial Cells Obtained for Asymptomatic High Breast Cancer Risk Nulliparous Premenopausal Women at Baseline, After Treatment With r-hCG at 90 Days, and at 270 Days From Baseline</title>
          <population>No results were obtained</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Recombinant Human Chorionic Gonadotropin</title>
          <description>Patients receive recombinant human chorionic gonadotropin subcutaneously three times weekly. Treatment continues weekly for 90 days in the absence of unacceptable toxicity.&#xD;
recombinant human chorionic gonadotropin&#xD;
microarray analysis&#xD;
immunohistochemistry staining method&#xD;
laboratory biomarker analysis&#xD;
needle biopsy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jose Russo</name_or_title>
      <organization>Fox Chase Cancer Center</organization>
      <phone>215-728-4782</phone>
      <email>Jose.Russo@fccc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

